Posted On: 09/14/2013 9:34:20 PM
Post# of 72451
In the R&R presentation, slide #5, regarding the acquisition of PolyM, one of the bullets about the various types of assets received read as follows:
"Proprietary computational drug design technology" . Do you feel this is a hidden diamond in the acquisition and could greatly accelerate the development/reformulation/etc work of the entire Kard lab Division of CTIX as they move foreward?
For some reason, that seemed to shout out to me as something Dr M recognized or had heard about and realized it would be quite instrumental for the CTIX work going forward on all projects. I obviously have no clue if this is true or not, would appreciate your input as to the possibilities of this acquired piece of technology software. I somehow feel it could justify the entire cost of the acquisition if it does allow an advanced platform for working with molecules in progress.
I am going to ask Karin to ask Leo about it in her upcoming interview.
"Proprietary computational drug design technology" . Do you feel this is a hidden diamond in the acquisition and could greatly accelerate the development/reformulation/etc work of the entire Kard lab Division of CTIX as they move foreward?
For some reason, that seemed to shout out to me as something Dr M recognized or had heard about and realized it would be quite instrumental for the CTIX work going forward on all projects. I obviously have no clue if this is true or not, would appreciate your input as to the possibilities of this acquired piece of technology software. I somehow feel it could justify the entire cost of the acquisition if it does allow an advanced platform for working with molecules in progress.
I am going to ask Karin to ask Leo about it in her upcoming interview.
(0)
(0)
